Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
NicOx |
---|---|
Information provided by: | NicOx |
ClinicalTrials.gov Identifier: | NCT00621881 |
This is an open-label study that will compare the pharmacokinetic and safety effects of naproxcinod in hepatic impaired patients vs. matching healthy subjects.
Condition | Intervention | Phase |
---|---|---|
Liver Disease |
Drug: naproxcinod |
Phase I |
Study Type: | Interventional |
Study Design: | Basic Science, Non-Randomized, Open Label, Active Control, Parallel Assignment, Pharmacokinetics Study |
Official Title: | A Phase 1, Repeated-Dose, Open-Label Study to Investigate the Pharmacokinetics and Safety of Naproxcinod 750 mg Bid Administered to Patients With Impaired Hepatic Function Compared to Matching Healthy Subjects |
Estimated Enrollment: | 24 |
Study Start Date: | January 2008 |
Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
750 mg naproxcinod
|
Drug: naproxcinod
750 mg bid
|
This is an open-label, non-randomized, parallel-group study that will be conducted at two study sites. Patients with hepatic impairment and matched healthy subjects will receive naproxcinod 750 mg bid for 6 days and qd for the last day.
Ages Eligible for Study: | 40 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | ( NicOx ) |
Study ID Numbers: | HCT3012-X-105 |
Study First Received: | February 12, 2008 |
Last Updated: | October 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00621881 |
Health Authority: | United States: Food and Drug Administration |
hepatic impairment |
Nitric Oxide Liver Diseases Naproxen |
Digestive System Diseases Naproxen-n-butyl nitrate Healthy |
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Cardiovascular Agents Pharmacologic Actions Nitric Oxide Donors |